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Zusammenfassung
Krebspatienten unterliegen im Vergleich zu Patienten
ohne Krebs einem erhöhten Risiko, venöse Thromboem-
bolien (VTE) zu erleiden. Gründe dafür sind die pro-
thrombotischen Effekte der Krebserkrankung selbst, aber
zusätzlich erhöhen auch iatrogene Faktoren wie Chemo-
therapie, Strahlentherapie, zentrale Venenkatheter und
operative Eingriffe das VTE-Risiko. Obwohl die krebsas-
soziierte Thrombose häufig ursächlich für Morbidität und
Mortalität ist, wird sie oft zu wenig diagnostiziert und
nicht adäquat behandelt. Es gibt zunehmende Hinweise
dafür, dass niedermolekulare Heparine (NMHs) in der se-
kundären Thromboseprophylaxe von Krebspatienten
von Vorteil sind. Sie sind nicht nur den Cumarinderivaten
in dieser Indikation mindestens ebenbürtig, sondern füh-
ren auch zu weniger Komplikationen, insbesondere, was
Blutungen anbelangt, und sind auch nicht mit den prakti-
schen Problemen der Warfarintherapie belastet. Darüber
hinaus gibt es basierend auf Studien zunehmend Hin-
weise, das NMHs durch mögliche Antitumor-Effekte das
Leben von Krebspatienten verlängern könnten. Aufgrund
der gegenwärtigen Datenlage sprechen einige Fakten
dafür, NMHs zunehmend in der Langzeittherapie von
Krebspatienten mit VTE einzusetzen.
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Summary
Patients with cancer are at increased risk of venous
thromboembolism (VTE) compared with patients without
cancer. This results from both the prothrombotic effects
of the cancer itself and iatrogenic factors, such as
chemotherapy, radiotherapy, indwelling central venous
devices and surgery, that further increase the risk of VTE.
Although cancer-associated thrombosis remains an im-
portant cause of morbidity and mortality, it is often un-
derdiagnosed and undertreated. However, evidence is
accumulating to support the use of low-molecular-weight
heparins (LMWHs) in the secondary prevention of VTE in
patients with cancer. Not only have LMWHs been shown
to be at least as effective as coumarin derivatives in this
setting, but they have a lower incidence of complica-
tions, including bleeding, and are not associated with the
practical problems of warfarin therapy. Furthermore, a
growing number of studies indicate that LMWHs may
improve survival among patients with cancer due to a
possible antitumor effect. Current evidence suggests that
LMWHs should increasingly be considered for the long-
term management of VTE in patients with cancer.
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Frequency of Venous Thromboembolism in Cancer
Patients
Venous thromboembolic disease (VTE) is a common and
often underdiagnosed condition in cancer patients. It may be a
presenting feature of occult malignancy, a life-threatening
complication of early or advanced cancer, or a sequela of can-
cer therapy. Most clinical studies designed to determine the
true incidence of VTE in cancer patients have been neither
prospective nor have they included untreated patients. In the
1980s, the incidence of VTE in malignant disease was estimat-
ed to be approximately 15%, ranging from 7 to 30% depend-
ing on the tumor site [1]. However, more recently, incidence
rates of 8% have been reported which may reflect the more
widespread use of thromboprophylaxis in modern practice [2].
Cancer patients undergoing surgery have at least twice the
risk of postoperative deep venous thrombosis (DVT) and
more than three times the risk of fatal pulmonary embolism
(PE) than noncancer patients undergoing similar procedures
[3]. Only a few clinical studies have estimated the prevalence
of asymptomatic DVT in cancer patients. One study screened
298 hospice patients, and DVT was detected in 52% of the pa-
tients, mainly those with poor mobility [4]. The clinical impor-
tance of asymptomatic VTE is that it can evolve into sympto-
matic DVT and even life-threatening PE. Furthermore, VTE
is the second most common cause of death in patients hospi-
talized for solid tumors. This may also explain the fact that
VTE detection rates at autopsy may be as high as 50% [5].
Pathogenic mechanisms accounting for the development of
VTE in cancer patients include hypercoagulability due to
tumor cell activation of clotting, vessel wall injury, and stasis
[1, 6, 7]. Non-tumor-derived factors leading to an additional
risk of VTE in cancer patients include advanced age, immobil-
ity, venous stasis, previous VTE and hereditary thrombophilia
[7]. In addition, several iatrogenic factors can also increase the
risk of thrombosis, including surgical procedures, chemothera-
py, radiotherapy and indwelling central venous devices [8].
Thromboprophylaxis in Cancer Patients
Patients with cancer who undergo surgery have a much higher
risk of postoperative VTE than non-cancer patients [8]. A se-
ries of trials has shown that low-dose unfractionated heparin
(UFH) and low-molecular-weight heparins (LMWHs) reduce
the frequency of postoperative VTE [9–12]. In many of these
studies, cancer patients have been included but not separately
analyzed. In one large trial of patients undergoing surgery for
intra-abdominal and pelvic malignancies, administration of
5,000 units of dalteparin was shown to be significantly more
effective than 2,500 units, without increasing the risk of bleed-
ing [13]. In another study of 631 patients who underwent
venographic assessment following elective abdominal or
pelvic cancer surgery, enoxaparin, 40 mg once daily, was as ef-
fective as UFH, with DVT occurring in 14.7 and 18.2% of pa-
tients, respectively [14]. Thus, current evidence indicates that
LMWHs are at least as effective as UFH in reducing postop-
erative DVT and PE, with additional advantages due to the
convenience of once-daily dosing.
The optimal duration of initial postoperative thromboprophy-
laxis in cancer patients is still under consideration. Bergqvist
et al. [15] studied the effect of a prolonged prophylaxis (21
days) with enoxaparin 40 mg or placebo after initial treatment
with enoxaparin for 7 days in patients with surgery for abdom-
inal or pelvic cancer. The rate of VTE after 4 weeks was sig-
nificantly higher in the placebo group (12%) than in the
enoxaparin group (4.8%). Similar results were shown by Ras-
mussen et al. [16] in the FAME study in which 590 patients re-
ceived 5,000 units of dalteparin daily for 1 week and were then
randomized to receive a further 3 weeks of dalteparin therapy
or no further thromboprophylaxis. Prolonged thrombopro-
phylaxis was associated with a significant reduction in the inci-
dence of VTE from 19.6 to 8.8%.
Non-surgical cancer therapies also increase the risk of VTE.
Cancer patients receiving chemotherapy account for 13% of
the overall prevalence of VTE in the population [17]. Further
studies are required before recommendations can be made re-
garding the use of thromboprophylaxis in cancer patients re-
ceiving chemotherapy. However, in its 2004 consensus docu-
ment, the American College of Chest Physicians (ACCP)
made a Grade 1A recommendation that thromboprophylaxis
appropriate for the current risk state should be routinely ad-
ministered to hospitalized cancer patients who are bedridden
with acute illness [8].
The incidence of catheter-related thrombosis (CRT) in cancer
patients with long-term indwelling central venous catheters
(CVCs) is highly variable. In a large study of 439 cancer pa-
tients undergoing chemotherapy for at least 12 weeks, the ad-
ministration of dalteparin (5,000 units) did not reduce the fre-
quency of CRT compared with placebo (3.7 vs. 3.4%, respec-
tively; p = 0.88) [18]. Given the low incidence of CRT in can-
cer patients with CVCs, routine thromboprophylaxis cannot
be recommended [8].
Treatment of VTE in Cancer Patients
The current standard for initial treatment of patients with
VTE consists of intravenous UFH or subcutaneous LMWH.
Recently, large clinical trials have shown that LMWHs have
equivalent efficacy and safety to UFH, and may even be ad-
ministered in an outpatient setting [19–21]. LMWHs have sev-
eral pharmacological advantages compared with UFH, which
include once- or twice-daily subcutaneous dosing without rou-
tine laboratory monitoring [22].
Anticoagulant regimens are generally the same for patients
with or without cancer. Although standard therapy for acute
VTE is highly effective in many patients, cancer patients have
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a 3- to 6-fold increased risk of bleeding and/or recurrent
thrombosis during oral anticoagulant therapy, compared with
non-cancer patients [23–25]. Furthermore, oral anticoagulant
therapy may be problematic in cancer patients because of
drug interactions, malnutrition, vomiting and liver dysfunc-
tion, all of which may lead to unpredictable levels of anticoag-
ulation. Standard treatment with heparins (UFH or LMWH)
and oral anticoagulants should only be administered in the ab-
sence of obvious bleeding risks, and reduced doses should be
used in patients at risk of bleeding (table 1). Cancer patients
with acute DVT and active bleeding cannot generally receive
anticoagulant therapy, and there are no standardized an-
tithrombotic regimens in this setting. In some institutions, in-
ferior vena cava filters are inserted in patients with a high risk
of PE, but this approach can be problematical as secondary
thrombosis of the filter leading to recurrent DVT and fatal PE
has been reported [26, 27]. However, in patients with active
bleeding, inferior cava filter insertion may be the only option.
After hemostasis is achieved, reduced-dose LMWH therapy
should be commenced.
Treatment of Recurrent Thrombosis
Cancer patients have a 2- to 3-fold higher risk of recurrent
VTE despite conventional anticoagulant therapy, compared
with non-cancer patients [25, 28]. In the first large-scale study
of the prevention of recurrent VTE in patients with cancer,
the CLOT trial (Comparison of Low-molecular weight he-
parin versus Oral anticoagulant Therapy for the prevention of
venous thromboembolism in patients with cancer), the effica-
cy of the LMWH, dalteparin, was compared with coumarin
[29]. Patients with acute, symptomatic proximal DVT, PE or
both were randomized to receive once-daily dalteparin, 200
units/kg, for 5–7 days, then a coumarin derivative for 6
months, or dalteparin alone for 1 month, and a lower dose of
150 units/kg for a further 5 months. During the 6-month study
period, the risk of VTE was approximately halved in the dal-
teparin group (9%) compared with the oral anticoagulant
group (17%; p = 0.002), with no increase in the risk of major
bleeding (6 vs. 4%; p = 0.27). The long-term administration of
tinzaparin has also been evaluated in the management of
DVT [30]. Tinzaparin, 175 units/kg once daily, was as effective
as a warfarin-based regimen in the prevention of recurrent
VTE, with a lower risk of bleeding. The ACCP guidelines on
VTE prevention highlight the dalteparin and tinzaparin regi-
mens as approaches that have been shown to be effective [31].
LMWH and Survival in Cancer
Recent years have seen increasing interest in the possible sur-
vival benefits of LMWHs [32–34]. However, these data arise
from studies that were not primarily designed to assess cancer
mortality, and prognostic variables were not evenly distributed
among the treatment groups. The Fragmin Advanced Malig-
nancy Study (FAMOUS) was the first randomized, double-
blind trial to evaluate the effect of long-term LMWH therapy
(dalteparin) on survival in cancer patients with no underlying
VTE [35]. Patients received either once-daily dalteparin, 5,000
units, or placebo for 1 year. The study did not demonstrate
improved 1-year survival rates in patients with advanced ma-
lignancy, but post-hoc analysis showed a survival advantage at
17 months in a subgroup of patients with a ‘better prognosis’
(i.e. those surviving 17 months after randomization). Similarly,
post-hoc analysis of the CLOT study demonstrated a survival
benefit among patients without metastatic disease at entry
into the study who received dalteparin (probability of death,
20%) compared with oral anticoagulant (36%) [36].
In the Malignancy and Low Molecular-Weight Heparin Thera-
py (MALT) study, a survival benefit was shown among pa-
tients with advanced cancer who received a 6-week adminis-
tration of nadroparin, compared with placebo [37]. Several
different tumor types were included in this study, and a signif-
icant survival advantage was observed with LMWH, for both
the study population as a whole and the subgroup of ‘better
prognosis’ patients. Similar findings were reported in an earli-
er trial of patients with small-cell lung cancer: those treated
with UFH for 5 weeks had a higher 1-year survival rate (40%)
than untreated patients (30%) [38]. In another trial of patients
with small-cell lung cancer, standard combination chemother-
apy was administered alone or in combination with dalteparin
for 18 weeks. Median overall survival increased from 8.0
months with chemotherapy alone to 13.0 months with com-
bined therapy [39]. Similar survival benefits were observed in
patients with both limited and extensive disease who received
LMWH. In contrast, 2 recent studies of certoparin administra-
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Table 1. Cancer patients at low risk of bleeding who should receive full-
dose anticoagulant therapy, and patients requiring reduced intensity anti-
coagulation
Low risk of bleeding – standard anticoagulant therapy 
Patients considered to be cured from cancer, or in complete remission 
Hodgkin’s and non-Hodgkin’s lymphomas 
Primary tumor without high bleeding risk (e.g. cancer of breast, lung, 
pancreas, ovary) 
Tumor with only bone metastases 
Tumor with only lymph node metastases, or few and small metastases 
of visceral organs (e.g. lung, liver) 
Increased risk of bleeding – reduced intensity of anticoagulation 
Tumor or metastases in the brain 
Tumors that involve ulceration into the lumen of an organ 
(e.g. stomach, bowel, bladder) 
Macrohematuria in renal cancer 
Currently bleeding tumor 
Hereditary or acquired coagulopathy 
Thrombocytopenia (< 50,000 / µl)
tion in patients with advanced breast cancer or non-small cell
lung cancer did not show a survival benefit of LMWH admin-
istration, compared with placebo [40].
Although some of these observations arise from post-hoc
analyses, together these data suggest that LMWHs may have a
modifying effect on tumor biology, especially in patients with
non-metastatic disease. It is unlikely that the effect simply aris-
es due to a reduced frequency of fatal PE because there was no
obvious survival benefit during the acute treatment period, and
the benefits of LMWH therapy were observed for several
months afterwards [36–38]. Thus, a mechanism that is indepen-
dent of the antithrombotic effects of heparins may be responsi-
ble. LMWHs have been shown to modify tumor growth by
mechanisms that include inhibition of angiogenesis, tumor
growth factors, heparinase and thrombin generation [41, 42].
An antiangiogenic effect is an appealing possibility [43, 44] and
is consistent with the observations of the FAMOUS and CLOT
studies [35, 36] where a survival benefit was evident in patients
with limited disease and persisted beyond the treatment peri-
od. Heparins may also have direct effects on tumor cell activity,
influencing tumor cell invasion and metastasis [44].
Recommendations for Routine Thromboprophylaxis
with LMWH
Surgery in cancer patients is associated with a high risk of
VTE, and the administered dose of LMWH should take into
account the high-risk situation. There are several LMWHs on
the market, and manufacturers generally provide information
on the dose appropriate for high-risk patients. Although sev-
eral studies demonstrate the benefit of prolonged prophylaxis,
the optimal duration of postoperative thromboprophylaxis re-
mains unclear.
The ACCP recommend the use of thromboprophylaxis in
acutely ill medical patients, including patients with active can-
cer who are confined to bed with acute illness [8]. These pa-
tients are considered to be high-risk, and currently enoxaparin
and dalteparin are licensed in Germany for this situation.
While some studies have shown a survival benefit for cancer
patients who have received short-term LMWH, there is cur-
rently no evidence to support their routine use in cancer pa-
tients to increase survival.
Conclusion
Compared with non-cancer patients, patients with cancer
have a higher risk of VTE and recurrent VTE, in addition to
increased bleeding rates following oral anticoagulant thera-
py, and some degree of resistance to therapy with UFH. Sev-
eral LMWHs have demonstrated superior efficacy to UFH
or oral anticoagulant therapy in the prevention or treatment
of VTE, without increasing the risk of bleeding. These clini-
cal benefits and the well-documented disadvantages of older
therapies in cancer patients suggest that LMWH should be
increasingly considered for the management of cancer-asso-
ciated thrombosis.
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